Connect with us

Business

Moderna’s stock gains 3.5% after it completes enrollment in COVID-19 vaccine trial – MarketWatch

Published

on

post featured image
ADVERTISEMENT

Shares of Moderna Inc.
MRNA,
+4.36%
gained 3.5% in trading on Thursday after it said it has completed enrollment of 30,000 participants in the Phase 3 clinical trial for its COVID-19 vaccine candidate. The trial is being conducted in partnership with the National Institutes of Health and the Biomedical Advanced Research and Development Authority. The preclinical company also said that 25,650 participants have received their second and final dose of the experimental vaccine in the late-stage trial,…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

post featured image
How to tell if you’re flying on a Boeing Max 737 – Boing Boing
post featured image
Today’s mortgage rates — one rate on an upswing | November 24, 2020 – Fox Business
post featured image
Abercrombie & Fitch CEO says it has a playbook to deal with closures as Covid threatens to shutter stores – CNBC